Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949678 | 0.94 | MMP8 (0.54) | MMP8FDPSPKMKMT2ANAPRT | |
| SCHEMBL2429056 | 0.93 | MMP8 (0.49) | MMP8FDPSPKMKMT2ANAPRT | |
| SCHEMBL18039180 | 0.86 | CYP1A2 (0.50) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL2420345 | 0.86 | TBXAS1 (0.56) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL30178281 | 0.86 | TBXAS1 (0.56) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL2370955 | 0.85 | ALDH1A1 (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL30178278 | 0.85 | FDPS (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL20543866 | 0.85 | FDPS (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL21947585 | 0.85 | FDPS (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL8633006 | 0.85 | TDP1 (0.47) | PKMKMT2ANAPRTTBXAS1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| EP-2925750-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-0636621-B1 | Beta-mercapto-propanamide derivatives useful in the treatment of cardiovascular diseases | ZAMBON SPA (IT) | 1997-03-12 | — | — | EP | disclosed |
| US-5506259-A | β-mercapto-propanamide derivatives useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.P.A. (IT) | 1996-04-09 | — | — | US | disclosed |
| EP-0636621-A1 | Beta-mercapto-propanamide derivatives useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.p.A. (IT) | 1995-02-01 | — | — | EP | disclosed |
| CN-1072413-A | Amino acid derivative | HOFFMANN LA ROCHE (CH) | 1993-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | MMP8 4635/4885FDPS 20/4885PKM 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.